Recomendaciones de "No Hacer"
Una Recomendación de No Hacer es una indicación de abandonar una práctica clínica de escaso valor. El escaso valor lo determina el hecho de que la práctica no reporte ningún beneficio conocido para los pacientes y/o les ponga en riesgo de sufrir daños y además pueda suponer un derroche de recursos, sanitarios y/o sociales.
Las Recomendaciones de NO Hacer incluidas en el Catálogo son las que cumplen todos estos criterios.
Para solicitar la inclusión en el Catálogo, es preciso cumplimentar el formulario.
Ver más información sobre la Iniciativa NO Hacer
Se recomienda no administrar flumazenilo en pacientes con sospecha de intoxicación mixta, ingesta medicamentosa desconocida o riesgo de convulsiones, excepto en pacientes de los que se tenga certeza que se trata de intoxicación aislada por benzodiacepinas y no presenten dependencia a estas
Sociedad Científica: Sociedad española de Urgencias de Pediatría (SEUP)
https://portal.guiasalud.es/wp-content/uploads/2026/03/rnh_75_212.pdf
Barnett R, Grace M, Boothe P, Latozek K, Neal C, Legatt D et al. Flumazenil in drug overdose: randomized, placebo-controlled study to assess cost effectiveness. Crit Care Med. 1999;27(1):78-81.
Bartlett D. The coma cocktail: indications, contraindications, adverse effects, proper dose, and proper route. J Emerg Nurs. 2004;30(6):572-4.
Boccuzzi-Chmura L, Robertson DC. Flumazenil (romazicon) and the patient with benzodiazepine overdose: risks versus benefits. J Emerg Nurs. 1996;22(4):330-3.
Buckley NA, Dawson AH, Juurlink DN, Isbister GK. Who gets antidotes? choosing the chosen few. Br J Clin Pharmacol. 2016;81(3):402-7.
Chern CH, Chern TL, Hu SC, Lee CH, Deng JF. Complete and partial response to flumazenil in patients with suspected benzodiazepine overdose. Am J Emerg Med. 1995;13(3):372-5.
Clancy C. Cardiologic principles I: Electrophysiologic and electrocardiographic principles. En: Lewis S. Nelson, Mary Ann Howland, Neal A. Lewin, Silas W. Smith, Lewis R. Goldfrank, Robert S. Hoffman. Goldfrank's Toxicologic Emergencies, Eleventh Edition; 2019, p. 255.
Farcas I, Schölin L, Eddleston M. Could Flumazenil Be Used Pre-hospital by Intramuscular Injection for Coma due to Mixed Drug Overdose Not Responding to Naloxone?: A Systematic Review of the Evidence. Basic Clin Pharmacol Toxicol. 2025;136(3):70007.
García Peláez M, Martínez Sánchez L. Guía de actualización de antídotos en indicaciones toxicológicas. En: Nogué Xarau S, Salgado García EJ, Martínez Sánchez L. Nogué. Toxicología clínica, 2ª ed. Barcelona. 2025, p. 253-268.
Greller H, Gupta A. Benzodiazepine poisoning. En: UpToDate (Última actualización Enero 2024).
Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol. 2013;9(2):155-62.
Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. JAMA. 1995;274(7):562-9.
Howland MA. Antidotes in depth: Flumazenil. En: Lewis S. Nelson, Mary Ann Howland, Neal A. Lewin, Silas W. Smith, Lewis R. Goldfrank, Robert S. Hoffman. Goldfrank's Toxicologic Emergencies, Eleventh Edition; 2019, p. 1094-1098.
Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS et al; American Heart Association. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023;148(16):149-184.
Martínez Sánchez L, López Ávila J, Barasoain Millán A, Angelats Romero CM, Azkunaga Santibañez B, Molina Cabañero JC. Grupo de Trabajo de Intoxicaciones de la Sociedad Española de Urgencias de Pediatría. Acciones que no hay que hacer ante un paciente que ha contactado con un posible tóxico. 2021;94(5):285-292.
McDuffee AT & Tobias JD. Seizure after flumazenil administration in a pediatric patient. Pediatr Emerg Care. 1995; 11:186-187.
Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60.
Penninga EI, Graudal N, Ladekarl MB, Jürgens G. Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication-A Systematic Review with Meta-Analyses of Randomised Trials. Basic Clin Pharmacol Toxicol. 2016;118(1):37-44.
Perry HE, Shannon MW. Diagnosis and management of opioid- and benzodiazepine-induced comatose overdose in children. Curr Opin Pediatr. 1996;8(3):243-7.
Rama B. Rao. Neurologic principles. En: Lewis S. Nelson, Mary Ann Howland, Neal A. Lewin, Silas W. Smith, Lewis R. Goldfrank, Robert S. Hoffman. Goldfrank's Toxicologic Emergencies, Eleventh Edition; 2019, p. 344.
Razavizadeh AS, Zamani N, Ziaeefar P, Ebrahimi S, Hassanian-Moghaddam H. Protective effect of flumazenil infusion in severe acute benzodiazepine toxicity: a pilot randomized trial. Eur J Clin Pharmacol. 2021;77(4):547-554.
Seger DL. Flumazenil--treatment or toxin. J Toxicol Clin Toxicol. 2004;42(2):209-16.
Sivilotti ML. Flumazenil, naloxone and the 'coma cocktail'. Br J Clin Pharmacol. 2016;81(3):428-36.
Smith SW. Drugs and pharmaceuticals: management of intoxication and antidotes. EXS. 2010;100:397-460.
Thomson JS, Donald C, & Lewin K. Use of Flumazenil in benzodiazepine overdose. Emerg Med J. 2006; 23(2):162.
Veiraiah A, Dyas J, Cooper G, Routledge PA, Thompson JP. Flumazenil use in benzodiazepine overdose in the UK: a retrospective survey of NPIS data. Emerg Med J. 2012;29(7):565-9.
Weinbroum AA, Flaishon R, Sorkine P, Szold O, Rudick V. A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. Drug Saf. 1997;17(3):181-96.
Weinbroum A, Rudick V, Sorkine P, Nevo Y, Halpern P, Geller E et al. Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients. Crit Care Med. 1996;24(2):199-206.
Woolf AD, Erdman AR, Nelson LS, Caravati EM, Cobaugh DJ, Booze LL et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(3):203-33.
Zamani N, Hassanian-Moghaddam H, Zamani N. Strategies for the treatment of acute benzodiazepine toxicity in a clinical setting: the role of antidotes. Expert Opin Drug Metab Toxicol. 2022;18(6):367-379.
No prescribir acetato de megestrol para el tratamiento de la anorexia, pérdida ponderal o caquexia en personas mayores de 65 años, debido a su escaso beneficio clínico y elevado riesgo de efectos adversos graves. Valorar su uso únicamente de forma excepcional en el contexto de cuidados paliativos, tras una evaluación individualizada del balance beneficio-riesgo.
Sociedad Científica: Sociedad Española de Medicina Familiar y Comunitaria (SEMFyC)
https://portal.guiasalud.es/wp-content/uploads/2026/03/rnh_93_213.pdf
By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. doi: 10.1111/jgs.18372. Epub 2023 May 4.
Ruiz-García V, López-Briz E, Carbonell-Sanchís R, Gonzálvez-Perales JL,Bort-Martí S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews. [Internet] 2013;(3). Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004310.pub3/full
Ruiz-García V, López-Briz E, Carbonell-Sanchís R, Bort-Martí S, Gonzálvez Perales JL. A systematic review: Megestrol acetate for cachexia-anorexia syndrome. J Cachexia Sarcopenia Muscle. 2018; 9(3): 444-52.
Taylor JK, Pendleton N. Progesterone therapy for the treatment of non-cancer cachexia: a systematic review. BMJ Support Palliat Care. 2016; 6(3): 276-86.
Se recomienda no pautar precauciones de transmisión por contacto en pacientes adultos colonizados o infectados por enterobacterias productoras de beta-lactamasas de espectro extendido (E-BLEE) en unidades de hospitalización convencional de adultos en ausencia de brote
Sociedad Científica: Sociedad Española de Medicina Preventiva; Salud Pública y Gestión Sanitaria (SEMPSPGS)
https://portal.guiasalud.es/wp-content/uploads/2026/02/rnh_80_206_2.pdf
Hagiya H, Otsuka F. Increased evidence for no benefit of contact precautions in preventing extended-spectrum β-lactamases-producing Enterobacteriaceae: Systematic scoping review. Am J Infect Control. 2023;51(9):1056-62. doi: 10.1016/j.ajic.2023.01.018. PMID: 36736903.
Thompson P, Teter J, Atrubin K. Incidence of health care-associated extended-spectrum β-lactamase-positive patients before and after discontinuation of contact precautions. Am J Infect Control. 2020;48(1):52-5. doi: 10.1016/j.ajic.2019.06.016. PMID: 31358415.
Maechler F, Schwab F, Hansen S, Fankhauser C, Harbarth S, Huttner BD, Diaz-Agero C, Lopez N, Canton R, Ruiz-Garbajosa P, Blok H, Bonten MJ, Kloosterman F, Schotsman J, Cooper BS, Behnke M, Golembus J, Kola A, Gastmeier P; R-GNOSIS WP5 study group. Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial. Lancet Infect Dis. 2020;20(5):575-84. doi: 10.1016/S1473-3099(19)30626-7. PMID: 32087113.
Gottlieb LB, Walits E, Patel G, Schaefer S. Taking off the gown: Impact of discontinuing contact precautions for extended-spectrum β-lactamase (ESBL)-producing organisms. Antimicrob Steward Healthc Epidemiol. 2021;1(1):e31. doi: 10.1017/ash.2021.189. PMID: 36168477; PMCID: PMC9495408.
Kluytmans-van den Bergh MFQ, Bruijning-Verhagen PCJ, Vandenbroucke-Grauls CMJE, de Brauwer EIGB, Buiting AGM, Diederen BM, van Elzakker EPM, Friedrich AW, Hopman J, Al Naiemi N, Rossen JWA, Ruijs GJHM, Savelkoul PHM, Verhulst C, Vos MC, Voss A, Bonten MJM, Kluytmans JAJW; SoM Study Group. Contact precautions in single-bed or multiple-bed rooms for patients with extended-spectrum β-lactamase-producing Enterobacteriaceae in Dutch hospitals: a cluster-randomised, crossover, non-inferiority study. Lancet Infect Dis. 2019;19(10):1069-79. doi: 10.1016/S1473-3099(19)30262-2. PMID: 31451419.
Souverein D, Euser SM, Herpers BL, Hattink C, Houtman P, Popma A, Kluytmans J, Rossen JWA, Den Boer JW. No nosocomial transmission under standard hygiene precautions in short term contact patients in case of an unexpected ESBL or Q&A E. coli positive patient: a one-year prospective cohort study within three regional hospitals. Antimicrob Resist Infect Control. 2017;6:69. doi: 10.1186/s13756-017-0228-6. PMID: 28670449; PMCID: PMC5485576.
Tschudin-Sutter S, Lucet JC, Mutters NT, Tacconelli E, Zahar JR, Harbarth S. Contact Precautions for Preventing Nosocomial Transmission of Extended-Spectrum β Lactamase-Producing Escherichia coli: A Point/Counterpoint Review. Clin Infect Dis. 2017;65(2):342-7. doi: 10.1093/cid/cix258. PMID: 28379311.
Tschudin-Sutter S, Frei R, Schwahn F, Tomic M, Conzelmann M, Stranden A, Widmer AF. Prospective Validation of Cessation of Contact Precautions for Extended-Spectrum β-Lactamase-Producing Escherichia coli(1). Emerg Infect Dis. 2016 Jun;22(6):1094-7. doi: 10.3201/eid2206.150554. PMID: 27191171; PMCID: PMC4880108.
Metan G, Metin BC, Baştuğ Z, Tekin İ, Aytaç H, Çınar B, Zengin H, Ünal S. Cessation of Contact Precautions for Extended-Spectrum Beta-Lactamase (ESBL)-Producing Escherichia coli Seems to be Safe in a Nonepidemic Setting. Infect Control Hosp Epidemiol. 2017;38(11):1379-81. doi: 10.1017/ice.2017.198. Epub 2017 Sep 20. PMID: 28927480.
Zahar JR, Poirel L, Dupont C, Fortineau N, Nassif X, Nordmann P. About the usefulness of contact precautions for carriers of extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis. 2015;15:512. doi: 10.1186/s12879-015-1244-x. PMID: 26563141; PMCID: PMC4642679.
Bellini C, Eder M, Senn L, Sommerstein R, Vuichard-Gysin D, Schmiedel Y, Schlegel M, Harbarth S, Troillet N. Providing care to patients in contact isolation: is the systematic use of gloves still indicated? Swiss Med Wkly. 2022;152:w30110. doi: 10.4414/smw.2022.w30110. PMID: 35147391.
No iniciar tratamiento biológico sistémico en pacientes adultos con enfermedad inflamatoria intestinal (colitis ulcerosa o enfermedad de Crohn) sin haber realizado y documentado previamente una lista de verificación estandarizada de seguridad
Sociedad Científica: Sociedad Española de Patología Digestiva (SEPD)
https://portal.guiasalud.es/wp-content/uploads/2026/07/rnh_110_221.pdf
Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention,diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443-468. doi:10.1016/j.crohns.2013.12.013.
Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017;112(2):241-258.
Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2025;120(7):1447-1473. doi:10.14309/ajg.0000000000003541
Olivera PA, Lasa JS, Zubiaurre I, et al. Opportunistic infections in patients with inflammatory bowel disease treated with advanced therapies: a systematic review and meta-analysis of randomized controlled trials. J Crohns Colitis. 2023;17(2):199-210. doi:10.1093/ecco-jcc/jjac133.
Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929-936. doi:10.1053/j.gastro.2008.01.012.
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor neutralizing agent. N Engl J Med. 2001;345(15):1098-1104. doi:10.1056/NEJMoa011110.
Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gut. 2008;57(4):549-555.
Inflammatory Bowel Disease Group of the Chinese Society of Gastroenterology. Evidence-based consensus on opportunistic infections in inflammatory bowel disease. Intest Res. 2018;16(2):178-193.
No solicitar pruebas analíticas preoperatorias en pacientes pediátricos sanos, programados para procedimientos o cirugías menores, salvo que la exploración física y anamnesis lo justifiquen
Sociedad Científica: Sociedad Española de Cirugía Pediátrica (SECP)
https://portal.guiasalud.es/wp-content/uploads/2026/07/rnh_114_222.pdf
Choosing Wisely USA. Don´t perform routine preoperative hemostatic testing in an otherwise healthy child with no previous personal or family history of bleeding. American Society of Hematology (ASH) and American Society of Pediatric Hematology/Oncology (ASPHO). 2019.
https://ashpublications.org/bloodadvances/article/6/2/679/483556/The-ASH-ASPHO-Choosing-Wisely-Campaign-5
National Institute for Health and Care Excellence. Intravenous fluid therapy in children and young people in hospital. London: NICE; 2015.
O'Connor ME, Drasner K. Preoperative laboratory testing of children undergoing elective surgery. Anesth Analg. 1990 Feb;70(2):176-80.
Recommendations | Intravenous fluid therapy in children and young people in hospital| Guidance | NICE [Internet]. NICE; 2016 [citado 25 febrero de 2025]. Disponible en: https://www.nice.org.uk/guidance/ng29
Hackmann T, Steward DJ, Sheps SB. Anemia in pediatric day- surgery patients: prevalence and detection. Anesthesiology 1991;75:27 – 31.
Roy WL, Lerman J, McIntyre BG. Is preoperative hemoglobin testing justified in children undergoing minor elective surgery? Can J Anaesth 1991;38:700–3.
Mallick MS. Is routine pre-operative blood testing in children necessary? Saudi Med J. 2006 Dec;27(12):1831-4. PMID: 17143358.
Serafini G, Ingelmo PM, Astuto M, et al.; Italian Society of Pediatric and Neonatal Anesthesia and Intensive Care (SARNePI). Preoperative evaluation in infants and children: recommendations of the Italian Society of Pediatric and Neonatal Anesthesia and Intensive Care (SARNePI). Minerva Anestesiol. 2014; 80(4): 461-469.
Basel A, Bajic D. Preoperative evaluation of the pediatric patient. Anesthesiol Clin. 2018; 36(4): 689-700.
Asaf T, Reuveni H, Yermiahu T, et al. The need for routine pre-operative coagulation screening tests (prothrombin time PT/partial thromboplastin time PTT) for healthy children undergoing elective tonsillectomy and/or adenoidectomy. Int J Pediatr Otorhinolaryngol. 2001;61(3):217-222.
Alzahrani A, Othman N, Bin-Ali T, et al. Routine preoperative coagulation tests in children undergoing elective surgery or invasive procedures: Are they still necessary? Clin Med Insights Blood Disord.2019;12:1179545X18821158.
Chee YL, Crawford JC, Watson HG, Greaves M; British Committee for Standards in Haematology. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. Br J Haematol. 2008;140(5):496-504.
Becke K, Eich C, Höhne C, Jöhr M, Machotta A, Schreiber M, Sümpelmann R. Choosing Wisely in pediatric anesthesia: An interpretation from the German Scientific Working Group of Paediatric Anaesthesia (WAKKA). Paediatr Anaesth. 2018 Jul;28(7):588-596. doi: 10.1111/pan.13383. Epub 2018 May 30. PMID: 29851190.
Fletke KJ, Kaysin A, Jones S. Preoperative Evaluation in Children. Am Fam Physician. 2022 Jun 1;105(6):640-649.
Se recomienda no iniciar el tratamiento hipouricemiante con la dosis máxima aprobada del medicamento ni mantener una dosis baja si no se ha alcanzado el objetivo terapéutico de uricemia. El ajuste de la dosis debe realizarse de forma progresiva, en función de la respuesta clínica, los niveles séricos de ácido úrico y la tolerancia del paciente
Sociedad Científica: Sociedad Española de Reumatología (SER)
https://portal.guiasalud.es/wp-content/uploads/2026/02/rnh_51_207.pdf
Li X, Shao Q, Shen J, Ren S, Li L, Lu H, Chen S. Association between the initial dose urate-lowering drugs and gout flares in adult males with gout. Rheumatology (Oxford). 2024 May 3;63(6):1599-1606. doi: 10.1093/rheumatology/kead437. PMID: 37610331.
[Guía de práctica clínica para el manejo de pacientes con gota] [2020] [Grupo GuipClinGot de trabajo de la GPC para el Manejo de Pacientes con Gota] [Guía de práctica clínica]. https://www.ser.es/wp-content/uploads/2020/10/Gui%CC%81a-de-Pra%CC%81ctica-Cli%CC%81nica-parael-Manejo-de-la-Gota.pdf
Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, Hidaka Y, Taniguchi A, Fujimori S, Yamamoto T. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018 Feb;77(2):270-276. doi: 10.1136/annrheumdis-2017-211574. Epub 2017 Nov 4. PMID: 29102957; PMCID: PMC5867413.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25. PMID: 27457514.
Stamp LK, Frampton C, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Doherty M, Zhang W, Richardson H,
Sarmanova A, Christensen R. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatol. 2022 Jan;4(1):e53-e60. doi: 10.1016/S2665-9913(21)00319-2.
Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, Baumgartner S. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct;45(2):174-83. doi: 10.1016/j.semarthrit.2015.05.005. Epub 2015 May 21. PMID: 26190562.
No inicie tratamiento reductor de la uricemia en pacientes con hiperuricemia asintomática sin síntomas de artritis gotosa ni demostración fehaciente de depósito de urato (tofos)
Sociedad Científica: Sociedad Española de Reumatología (SER)
https://portal.guiasalud.es/wp-content/uploads/2026/04/rnh_52_214.pdf
Brest AN, Heider C, Mehbod H, Onesti G. Drug control of diuretic-induced hyperuricemia. JAMA. 1966;195(1):42-4.
de Vries A, Frank M, Liberman UA, Sperling O. Allopurinol in the prophylaxis of uric acid stones. Annals of the rheumatic diseases. 1966;25(6 Suppl):691-3. Epub 1966/11/01.
Gutman AB, Yu TF. Protracted uricosuric therapy in tophaceous gout. Lancet. 1957;273(7008):1258-60.
Nicotero JA, Scheib ET, Martinez R, Rodnan GP, Shapiro AP. Prevention of hyperuricemia by allopurinol in hypertensive patients treated with chlorothiazide. N Engl J Med. 1970;282(3):133-5.
Yu TF, Gutman AB. Principles of current management of primary gout. Am J Med Sci. 1967;254(6):893-907
Riche-e P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42.
Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017;56(7):1246
En la urticaria crónica no se recomienda el uso prolongado de corticoides orales o tópicos. En caso de exacerbaciones graves pueden considerarse ciclos cortos (habitualmente ≤10 días), debido a la ausencia de beneficio sostenido y al riesgo de efectos adversos asociados a ciclos más largos
Sociedad Científica: Sociedad Española de Alergología e Inmunología Clínica (SEAIC)
Áreas Temáticas:
https://portal.guiasalud.es/wp-content/uploads/2026/04/rnh_85_215.pdf
Desmond V., Alicandro T., Pepe P et al. Chronic Spontaneous urticaria: A review of Pathological mechanism, Diagnosis, Clinical management, and Treatment. EMJ. 2020; 5(1):29-39.
Zuberbier T, Abdul, Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, Ballmer-Weber B, Maurer M. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, andmanagement of urticaria. Allergy. 2022 Mar;77(3):734-766. doi: 10.1111/all.15090.
Zuberbier T, Bernstein JA, Maurer M. Chronic spontaneous urticaria guidelines: What is new? J Allergy Clin Immunol. 2022 Dec;150(6):1249-1255. doi: 10.1016/j.jaci.2022.10.004. Update in: J Allergy Clin Immunol. 2023Feb;151(2):580
Sabroe, R.A., Lawlor, F., Grattan, C.E.H., Ardern-Jones, M.R., Bewley, A., Campbell, L., Flohr, C., Leslie, T.A.,Marsland, A.M., Ogg, G., Sewell, W.A.C., Hashme, M., Exton, L.S., Mohd Mustapa, M.F., Ezejimofor, M.C. and(2022), British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021.Br J Dermatol, 186: 398-413. https://doi.org/10.1111/bjd.20892
Hacard F, Giraudeau B, d'Acremont G, Jegou MH, Jonville-Bera AP, Munck S, Pham BN, Mavoungou S,Cornillier H, Guillot B, Beylot-Barry M, Chosidow O, Maruani A. Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology. Br J Dermatol. 2021 Sep;185(3):658-660. doi: 10.1111/bjd.20415
Marta P La Forgia, Ana C Torre, Adrea Song, Carla A Ritchie, Iris Medina, Alicia Cannavo, Paula C Luna, Gabriel Gattolin, Maximiliano Gómez. Practical update for the diagnosis and treatment of chronic urticaria. Medicina(B Aires) 2023;83(5):772-792.
Alexandro W L Chu, Daniel G Rayner, Xiajing Chu, Lina Chen, Andrea Y H Dong, Susan Waswerman, Diane R Baker, Jared Sheikh, Joseph Moellman, David M Lang, Moshe Ben-Shoshan, Sammer K Mathur, Lisa A Beck,David A Kayan, Eric T Oliver, Rachel N Asiniwasis, Jeffrey Chan, Emily F Cole, Kathryn P Trayes, Winfred TFrazier, Lauren Runyon, Kathryn E Wheeler, Sanaz Eftekhari, Donna D Gardner, Tonya Winders, Jonathan ABernstein, Sarbjit S Saint, Derek k Chu. Topical corticosteroids for hives and itch (urticaria): Systematic review and Bayesian meta-analysis of randomized trials. Ann Allergy Asthma Immunol. 2024 Oct; 133 (4):437-444. E18. DOI:10.1016/J.ANAI.2024.06.003.
Xiajing Chu, Jason Wang, Leonardo Ologundudu, Romina Brignardello-Petersen, Gordon H Guyatt, Paul Oykhman, Jonathan A Bernstein, Sarbjit S Saini, Lisa A Beck, Susan Waswerman, Joseph Moellman, Dave AKhan, Moshe Ben-Shoshan, Diane R Baker, Eric T Oliver, Javed Sheikh, David Lang, Sameer K Mathur, TonyaWinders, Sanaz Eftekhari, Donna D Gardner, Lauren Runyon, Rachel N Asiniwasis, Emily F Cole, Jeffrey Chan,Kathryn E Wheeler, Kathryn P Trayes, Paul Tran, Derek K Chu. Efficacy and Safety of Systemic Corticosteroids for urticaria: A systematic Review and Meta-Analysis of Randomized Clinical Trials. J Allergy Clin Immunol Pract.2024 Jul; 12(7):1879-1889.e8. Doi:10.1016/ j.jaip.2024.04.016.
No utilizar etiquetas diagnósticas psiquiátricas en la primera valoración de personas que consultan en atención primaria por malestar emocional, cuando no presentan criterios completos de trastorno mental, riesgo suicida ni deterioro funcional moderado o grave. Se recomienda realizar seguimiento clínico y reevaluar antes de asignar un diagnóstico formal
Sociedad Científica: Sociedad Española de Medicina Familiar y Comunitaria (SEMFyC)
https://portal.guiasalud.es/wp-content/uploads/2026/04/rnh_95_216.pdf
Lobo AO, González RG, Salvanés FR. La derivación a salud mental de pacientes sin un trastorno psíquico diagnosticable. Aten Primaria. 2006; 38 (10): 563-9. doi: 10.1157/13095928
Ortiz A, Ibáñez V. Iatrogenia y prevención en salud mental. Rev Esp Salud Pública. 2011; 85 (6): 513-25. doi:10.1590/S1135-57272011000600002
Gérvas Camacho J, Pérez Fernández M. Uso y abuso del poder médico para definir enfermedad y factor de riesgo, en relación con la prevención cuaternaria. Gac Sanit. 2006: 20 (3): 66. doi: 10.1157/13101092
No utilizar fármacos como los opioides mayores y las benzodiacepinas para el tratamiento de las personas con fibromialgia
Sociedad Científica: Sociedad Española de Reumatología (SER)
https://portal.guiasalud.es/wp-content/uploads/2025/12/rnh_61_201.pdf
Rivera Redondo J, Díaz Del Campo Fontecha P, Alegre de Miquel C, Almirall Bernabé M, Casanueva Fernández B, Castillo Ojeda C, et al. Recommendations by the Spanish Society of Rheumatology on Fibromyalgia. Part 1: Diagnosis and Treatment. Reumatol Clin (Engl Ed). 2022 Mar;18(3):131-140.
Annemans L, Wessely S, Spaepen E, Caekelbergh K, Caubere JP, Le Lay K, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58:895–902.
Lamotte M, Maugars Y, Le Lay K, Taieb C. Health economic evaluation of outpatient management of fibromyalgia patients and the costs avoided by diagnosing fibromyalgia in France. Clin Exp Rheumatol. 2010;28 6 Suppl 63:S64–70.
Aïni K, Curelli-Chéreau A, Antoine P. The subjective experience of patients livingwith fibromyalgia: A qualitative analysis. Annales Medico-Psychologiques. 2010;168:255–62.
Escudero-Carretero MJ, Garcia-Toyos N, Prieto-Rodriguez M.A., Perez-Corral O., March-Cerda J.C., Lopez-Doblas M. Fibromyalgia: Patient perception on their disease and health system. Qualitative research study. Reumatol Clin. 2010;6:16-22.
National Institute for Health and Care Excellence (NICE). Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain [Internet]. London: NICE; 2021.
